Aimm Therapeutics B.v.

Crucell Holland B.v.

Medimmune Limited

Kling Biotherapeutics B.v.

Adrianus Quirinus Bakker

Tim Beaumont

Hergen Spits

Mark Jeroen Kwakkenbos

Alexander Berthold Hendrik Bakker

Etsuko Yasuda

Koen Wagner

Marja Van Meijer

Martijn Kedde

Sonja Van Den Oudenrijn

Marijn Aletta Gillissen

Mette Deborah Hazenberg

Pauline Marie Louise Meester-Rood

Cornelis Adriaan De Kruif

Mark Throsby

The invention provides human AML-specific binding compounds that are able to bind a cell surface component of AML cells. Therapeutic uses of binding compounds against AML are also provided.

Means and methods for counteracting myeloproliferative or lymphoproliferative disorders

The invention provides antibodies and functional equivalents thereof which are capable of specifically binding RSV. Nucleic acid sequences encoding said antibody, as well as antibody producing cells and methods for producing said antibody are also provided.

RSV-specific binding molecule

The invention provides means and methods for selecting and producing stable antibodies against an antigen of interest, using stable ex vivo B cell cultures.

Means and methods for producing stable antibodies

The invention provides means and methods for modulating the occurrence of somatic hypermutations in antibody producing plasmablast-like B-cells.

Means and methods for producing high affinity antibodies

The invention provides means and methods for producing high-affinity antibodies against an antigen of interest, usually stable B-cell cultures.

RSV specific binding molecule

Described are means and methods for producing high-affinity antibodies against an antigen of interest, using stable B-cell cultures.

The invention relates to the generation of immunoglobulin libraries and the identification and production of immunoglobulins having a specific functionality of interest.

Method for preparing immunoglobulin libraries

Provided is a human C-type lectin, binding molecules that specifically bind to the human C-type lectin, nucleic acid molecules encoding the binding molecules or the human C-type lectin, compositions comprising the binding molecules or the human C-type lectin and methods of identifying or producing the binding molecules. The human C-type lectin is specifically expressed on myeloid cells and binding molecules capable of specifically binding to the human C-type lectin can be used in the diagnosis, prevention and/or treatment of neoplastic disorders and diseases.

Binding molecules for the treatment of myeloid cell malignancies

The present invention provides binding molecules, such as human binding molecules, that bind to and stimulate the human OX40-receptor. The invention also provides nucleic acids encoding such binding molecules. Methods for producing such binding molecules are also provided by the present invention. The binding molecules and nucleic acids are useful in the stimulation of human T-cells and can be used to enhance antigen-specific immune responses.

Agonistic binding molecules to the human OX40 receptor

The present invention provides a human C-type lectin, binding molecules that specifically bind to the human C-type lectin, nucleic acid molecules encoding the binding molecules or the human C-type lectin, compositions comprising the binding molecules or the human C-type lectin and methods of identifying or producing the binding molecules. The human C-type lectin is specifically expressed on myeloid cells and binding molecules capable of specifically binding to the human C-type lectin can be used in the diagnosis, prevention and/or treatment of neoplastic disorders and diseases.

Growing community of inventors

Hoorn, Netherlands

Adrianus Quirinus Bakker